Trial Profile
A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs A-166 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Laryngeal cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Salivary gland cancer; Skin cancer; Solid tumours; Tongue cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Klus Pharma
- 02 Aug 2023 Status changed from active, no longer recruiting to completed.
- 31 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.